RenovoRx (NASDAQ:RNXT) Earns “Hold” Rating from Maxim Group

Maxim Group restated their hold rating on shares of RenovoRx (NASDAQ:RNXT) in a research note issued to investors on Wednesday, Benzinga reports.

Separately, Roth Mkm dropped their price objective on shares of RenovoRx from $14.00 to $13.00 and set a buy rating for the company in a report on Friday, August 18th.

RenovoRx Stock Down 4.1 %

RNXT opened at $0.60 on Wednesday. The firm has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.74. RenovoRx has a 52 week low of $0.55 and a 52 week high of $5.75. The company has a market capitalization of $6.41 million, a PE ratio of -0.64 and a beta of 0.31.

RenovoRx (NASDAQ:RNXT) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.03. As a group, sell-side analysts expect that RenovoRx will post -1.05 earnings per share for the current year.

Institutional Trading of RenovoRx

Several hedge funds have recently made changes to their positions in the business. Level Four Advisory Services LLC raised its position in shares of RenovoRx by 50.0% during the 2nd quarter. Level Four Advisory Services LLC now owns 15,000 shares of the company’s stock valued at $34,000 after buying an additional 5,000 shares in the last quarter. Geode Capital Management LLC raised its position in shares of RenovoRx by 16.6% during the 1st quarter. Geode Capital Management LLC now owns 42,100 shares of the company’s stock valued at $147,000 after buying an additional 5,993 shares in the last quarter. Vanguard Group Inc. purchased a new stake in shares of RenovoRx during the 1st quarter valued at about $32,000. Bank of America Corp DE purchased a new stake in shares of RenovoRx during the 1st quarter valued at about $44,000. Finally, Colony Group LLC purchased a new stake in shares of RenovoRx during the 3rd quarter valued at about $32,000. 2.29% of the stock is currently owned by hedge funds and other institutional investors.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.